Akari Therapeutics
NASDAQ: AKTXTampa, US · Incorporated in United Kingdom · 15 employees on LinkedIn · 1 known investors
Find your way into Akari Therapeutics
1,114 people in our graph share verified history with the Akari Therapeutics team — schools, employers, funds. One of them is your warm intro.
Teresa Chanunlockedknows Abizer Gaslightwala · together at Johnson & Johnson (overlapped)
×6knows the team · via Massachusetts Institute of Technology
knows the team · via MIT Sloan School of Management
×2knows the team · via Columbia University
knows the team · via Amgen
knows the team · via Johnson & Johnson
Akari Therapeutics is an oncology biotechnology company developing antibody drug conjugates (ADCs) built on a proprietary PH1 spliceosome-modulating payload that disrupts RNA splicing in cancer cells. Its pipeline includes AKTX-101, targeting the Trop2 receptor, and AKTX-102, targeting CEACAM5 across solid tumors.
Founders & leadership
KF
Kameel FaraginInterim Chief Financial OfficerKameel Farag has over 20 years of finance experience in biopharmaceuticals, including roles as CFO at Aspen Neuroscience and senior finance positions at Ionis Pharmaceuticals and Amgen, and currently serves as an advisor and board member to biotechnology companies.
AG
Abizer GaslightwalainChief Executive OfficerAbizer Gaslightwala is Chief Executive Officer of Akari Therapeutics, an oncology biotechnology company developing antibody drug conjugates. He previously held senior roles at Jazz Pharmaceuticals, Amgen, Pfizer, and Johnson & Johnson.
GR
Gur RoshwalbinExecutiveGur Roshwalb is an executive with experience in clinical medicine, sell-side research, buy-side investing, and clinical development, having helped build and finance private and public life science companies.
CR
Clive RichardsoninChief Executive Officer2018–2022
DE
Dov ElefantExecutive
RP
Ray PrudoNamed on SEC filing
Board
SP
Samir PatelBoard director
SP
Sandip PatelBoard director
HH
Hoyoung HuhBoard director
RB
Rob BazemoreBoard director
JN
Jim NealBoard director
SU
Stuart UngarBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$126.3M disclosed across 9 rounds · 2015–2026
▶$1.8MraisedJun 2026 · 6 investors · Other Health CareRule 506(b)
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunityfinance.yahoo.com · Jul 2026
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestonesglobenewswire.com · Jun 2026 · press release
▶$1.8MraisedJun 2026 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ray PrudoDirector
- Rob BazemoreDirector
- Hoyoung HuhDirector
- Samir PatelDirector
- Sandip PatelDirector
- Abizer GaslightwalaExecutive Officer, Director
- Kameel FaragExecutive Officer
- Jim NealDirector
- Offering amount
- $5.5M
- Amount sold
- $1.8M
- Sales commissions
- $125K
- Placement agents
- Paulson Investment Company, LLC
- First sale
- May 2026
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
▶$6.3MraisedOct 2025 · 4 investors · Other Health CareRule 506(b)
▶$6.3MraisedOct 2025 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Samir PatelDirector
- Sandip PatelDirector
- Ray PrudoDirector
- Hoyoung HuhDirector
- Kameel FaragExecutive Officer
- Rob BazemoreDirector
- Abizer GaslightwalaExecutive Officer, Director
- Jim NealDirector
- Offering amount
- $6.3M
- Amount sold
- $6.3M
- Sales commissions
- $180K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Oct 2025
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
▶$2MraisedJan 2024 · 2 investors · Other Health CareRule 506(b)
▶$2MraisedJan 2024 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Wendy DiCiccoExecutive Officer
- Dr. Ray PrudoDirector
- Rachelle JacquesDirector, Executive Officer
- Wa'el HashadDirector
- Michael GrissingerDirector
- Samir PatelDirector
- Donald WilliamsDirector
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $100K
- Placement agents
- Paulson Investment Company LLC
- First sale
- Dec 2023
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
▶$2MraisedOct 2023 · 11 investors · Other Health CareRule 506(c)
▶$2MraisedOct 2023 · 11 investors · Other Health Care
Rule 506(c)Officers, directors & promoters on the filing
- Donald WilliamsDirector
- Wendy DiCiccoExecutive Officer
- Michael GrissingerDirector
- Rachelle JacquesExecutive Officer, Director
- Wa'el HashadDirector
- Dr. Ray PrudoDirector
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $149.6K
- Placement agents
- PAULSON INVESTMENT COMPANY LLC
- First sale
- Oct 2023
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06c
▶$12.8MraisedSep 2022 · 21 investors · BiotechnologyRule 506(b)
▶$12.8MraisedSep 2022 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael GrissingerDirector
- Melissa Bradford-KlugExecutive Officer
- Donald WilliamsDirector
- Torsten HombeckExecutive Officer
- Ray PrudoDirector
- Rachelle JacquesExecutive Officer, Director
- Stuart UngarDirector
- James HillDirector
- Miles NunnExecutive Officer
- David ByrneDirector
- Offering amount
- $12.8M
- Amount sold
- $12.8M
- Sales commissions
- $898.5K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Sep 2022
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
▶$12.3MraisedJul 2021 · 62 investors · BiotechnologyRule 506(b)
▶$12.3MraisedJul 2021 · 62 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael GrissingerDirector
- Stuart UngarDirector
- Peter FeldschreiberDirector
- David ByrneDirector
- Ray PrudoDirector
- Donald WilliamsDirector
- James HillDirector
- Clive RichardsonExecutive Officer, Director
- Offering amount
- $12.3M
- Amount sold
- $12.3M
- Sales commissions
- $933K
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Jul 2021
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
▶$9.6MraisedMar 2020 · 53 investors · BiotechnologyRule 506(b)
▶$9.6MraisedMar 2020 · 53 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stuart UngarDirector
- David ByrneDirector
- Donald WilliamsDirector
- Michael GrissingerDirector
- Clive RichardsonExecutive Officer, Director
- Peter FeldschreiberDirector
- Ray PrudoDirector
- James HillDirector
- Offering amount
- $9.6M
- Amount sold
- $9.6M
- Sales commissions
- $764.4K
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Feb 2020
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
▶$4.5MraisedJul 2019 · 45 investors · BiotechnologyRule 506(b)
▶$4.5MraisedJul 2019 · 45 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Clive RichardsonExecutive Officer, Director
- Dov ElefantExecutive Officer, Director
- Ray PrudoExecutive Officer, Director
- James HillDirector
- Stuart UngarDirector
- David ByrneDirector
- Donald WilliamsDirector
- Peter FeldschreiberDirector
- Michael GrissingerDirector
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Sales commissions
- $337.5K
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Jun 2019
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Robinhood19 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall St18 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Seeking Alpha16 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingView16 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwits13 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Akari Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - BioSpacebiospace.com · Aug 2026
Akari Therapeutics Q2 Results: Net loss widens to $4.8 millionscanx.trade · Aug 2026
Akari Therapeutics Completes Consolidated PIPE Closing, Receives $8.3 Million in Total Q2 2026 Capital | Quiver Quantitativequiverquant.com · Jun 2026Frequently asked questions
- What does Akari Therapeutics do?
- Akari Therapeutics is an oncology biotechnology company developing antibody drug conjugates (ADCs) built on a proprietary PH1 spliceosome-modulating payload that disrupts RNA splicing in cancer cells. Its pipeline includes AKTX-101, targeting the Trop2 receptor, and AKTX-102, targeting CEACAM5 across solid tumors.
- Who are Akari Therapeutics's investors?
- Akari Therapeutics's investors include New Enterprise Associates (NEA).
- How much funding has Akari Therapeutics raised?
- Akari Therapeutics has disclosed $126.3M raised across 9 rounds.
- Where is Akari Therapeutics headquartered?
- Akari Therapeutics is headquartered in Tampa, US.